GURU.Markets stock price, segment price, and overall market index valuation
The company's share price HOOKIPA Pharma Inc.
Hempacco, a hemp cigarette company, is a highly speculative stock. Its price is driven not by financial performance, but by distribution news and regulatory changes.
Share prices of companies in the market segment - Pharma immune
HOOKIPA Pharma is a biopharmaceutical company developing a new class of arenavirus-based immunotherapeutics for the treatment of cancer and infectious diseases. We've categorized it under "Pharma: Immunology." The chart below shows the dynamics of this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
HOOKIPA Pharma is an Austrian biotech company developing a new class of immunotherapeutic drugs based on arenaviruses. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how HOOKIPA shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
HOOK - Daily change in the company's share price HOOKIPA Pharma Inc.
For HOOKIPA Pharma Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma immune
HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapy for the treatment of cancer and infectious diseases. This is at the forefront of biotechnology. The chart below shows the volatility in this sector, reflecting the risks and potential associated with HOOK's developments.
Daily change in the price of a broad market stock, index - GURU.Markets
HOOKIPA Pharma is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization HOOKIPA Pharma Inc.
For HOOKIPA Pharma, year-over-year performance is a reflection of its unique immunotherapy platform. Its 12-month market cap is entirely dependent on clinical trial data. The success of its approach, which uses arenaviruses to stimulate the immune response, could be a breakthrough in the treatment of both cancer and infectious diseases.
Annual dynamics of market capitalization of the market segment - Pharma immune
As an early-stage biotech company, HOOKIPA is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its vaccine platform. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
HOOKIPA Pharma is an immuno-oncology company whose shares are betting on a new generation of cancer drugs. Its performance is completely disconnected from the market and is determined by news of the clinical successes or failures of its platform. It's a high-risk play, where scientific data can change everything overnight.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization HOOKIPA Pharma Inc.
HOOKIPA is an immuno-oncology company with a unique platform. Its monthly performance is driven by progress in its clinical programs and partnerships, particularly with Gilead. News of key research milestones are key drivers.
Monthly dynamics of market capitalization of the market segment - Pharma immune
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapies for the treatment of cancer and infectious diseases. It's an innovative platform. The dynamics of the biotech sector reflect hopes for breakthroughs. HOOKIPA's story is a gamble that its unique approach to "training" the immune system will prove effective.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
HOOKIPA Pharma is a biotech company developing a new class of immunotherapy based on its arenavirus platform. Its value depends almost entirely on the success of clinical trials. The overall market price has little impact on HOOKIPA; its shares are driven by scientific news, which can cause explosive growth or decline on any given day.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization HOOKIPA Pharma Inc.
HOOKIPA Pharma is a biotech company developing arenavirus-based immunotherapies for the treatment of cancer and infectious diseases. Its weekly stock price is highly volatile, depending on clinical trial news.
Weekly dynamics of market capitalization of the market segment - Pharma immune
HOOKIPA Pharma is developing a new immunotherapy platform for infectious diseases and cancer. This is a cutting-edge, yet risky, area of biotech. The chart below will help determine whether HOOKIPA's share price fluctuations are a reaction to its own scientific data or reflect overall investor sentiment toward the entire immunology sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
HOOKIPA is a biotech company whose stock moves on news about clinical trials. This chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
HOOK - Market capitalization of the company HOOKIPA Pharma Inc.
HOOKIPA Pharma's market capitalization reflects investor confidence in its unique platform for developing arenavirus-based immunotherapy. Its volatile price is driven by news of clinical trials in oncology and infectious diseases. It represents a high-risk bet on a new scientific approach.
HOOK - Share of the company's market capitalization HOOKIPA Pharma Inc. within the market segment - Pharma immune
HOOKIPA Pharma is a biotech company developing a new class of immunotherapy based on arenaviruses. Its market share in the pharmaceutical sector is very small. Its market capitalization reflects the market's valuation of its innovative scientific platform and its potential for treating infectious diseases and cancer.
Market capitalization of the market segment - Pharma immune
The chart below shows the overall value of the biotech sector. HOOKIPA Pharma is developing a new generation of immunotherapy based on arenaviruses. Its platform can be used for both cancer treatment and vaccine development. Its market position reflects the success of its unique technology.
Market capitalization of all companies included in a broad market index - GURU.Markets
HOOKIPA is an Austrian biotech company developing a new class of arenavirus-based immunotherapies for the treatment of cancer and infectious diseases. Its market capitalization is a bet on this platform. The chart below shows the economic weight of companies with innovative platforms.
Book value capitalization of the company, segment and market as a whole
HOOK - Book value capitalization of the company HOOKIPA Pharma Inc.
HOOKIPA's foundation is its unique arenavirus-based scientific platform for developing immunotherapies for cancer and infectious diseases. The chart tells the story of a biotech company investing in its innovative approach, where its book value is generated both by its own developments and partnerships with major pharmaceutical companies.
HOOK - Share of the company's book capitalization HOOKIPA Pharma Inc. within the market segment - Pharma immune
HOOKIPA Pharma is developing arenavirus-based immunotherapy. The chart shows its share of actual R&D and manufacturing assets. These include its laboratories and a manufacturing plant where a unique platform for "training" the immune system is being created.
Market segment balance sheet capitalization - Pharma immune
HOOKIPA Pharma is a biotech company developing arenavirus-based immunotherapy. Their value lies in their unique platform and data. The book value chart shows the value of their R&D centers, which are merely a tool for implementing their scientific idea.
Book value of all companies included in the broad market index - GURU.Markets
HOOKIPA's resources include laboratories and in-house manufacturing facilities for developing a new class of immunotherapy based on arenaviruses. The diagram shows how the company built this unique production platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - HOOKIPA Pharma Inc.
HOOKIPA Pharma uses an innovative platform to develop immunotherapeutic drugs. Its assets are its technology. The chart below reflects its belief in its scientific approach. Its market capitalization, like that of many biotech companies, is a bet on the success of clinical trials, not a valuation of its tangible assets.
Market to book capitalization ratio in a market segment - Pharma immune
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapies for the treatment of cancer and infectious diseases. Its valuation is based on the potential of its unique scientific platform. The chart shows a high premium to its stock, reflecting hopes for breakthrough drugs.
Market to book capitalization ratio for the market as a whole
HOOKIPA Pharma uses innovative technology to develop immunotherapeutic drugs. The company's value lies in its scientific platform. This chart illustrates a typical biotech situation: the market valuation based on the technology's potential is many times greater than the value of the tangible assets.
Debts of the company, segment and market as a whole
HOOK - Company debts HOOKIPA Pharma Inc.
HOOKIPA Pharma is a biotech company developing a new class of immunotherapy based on arenaviruses. This chart shows how it funds its innovative but risky research. The company raises capital through partnerships (such as with Gilead) and equity issuances to advance its candidates through clinical trials.
Market segment debts - Pharma immune
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapy for the treatment of cancer and infectious diseases. This is an innovative but risky technology. This chart reflects the company's financial needs to advance its unique platform through clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio HOOKIPA Pharma Inc.
HOOKIPA Pharma is a biotech company developing immunotherapeutic drugs. This chart shows its financial structure. As with most development-stage biotechs, debt is a huge risk. Financing must be equity-based.
Market segment debt to market segment book capitalization - Pharma immune
HOOKIPA Pharma is a biopharmaceutical company developing a new class of immunotherapy based on arenaviruses. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its innovative and risky research in infectious diseases and cancer.
Debt to book value of all companies in the market
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapy for the treatment of cancer and infectious diseases. This is a breakthrough, but risky, technology. This graph of total market debt serves as an indicator of the financial system's willingness to finance long-term research with uncertain outcomes.
P/E of the company, segment and market as a whole
P/E - HOOKIPA Pharma Inc.
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapeutics for the treatment of cancer and infectious diseases. This chart reflects investor confidence in its innovative platform. The price action is speculative and dependent on clinical trial results.
P/E of the market segment - Pharma immune
HOOKIPA Pharma is a biotech company developing a new class of immunotherapy based on its arenavirus platform. This technology is designed to treat cancer and infectious diseases by stimulating a powerful T-cell response. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value innovative vaccine and immunotherapy platforms.
P/E of the market as a whole
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapies for the treatment of cancer and infectious diseases. Its valuation is a pure bet on its scientific platform. It is not tied to the general economic cycles shown by this chart, but depends on clinical trial data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company HOOKIPA Pharma Inc.
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapies for the treatment of cancer and infectious diseases. This chart reflects investor confidence in its innovative platform. Future profits depend on the success of clinical trials and partnerships with major pharmaceutical companies.
%20P%2FE%20HOOKIPA%20Pharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-HOOKIPA-Pharma-Inc.&v=1772513629022 "Chart of the company's future (projected) P/E HOOKIPA Pharma Inc.")
Future (projected) P/E of the market segment - Pharma immune
HOOKIPA Pharma is a biopharmaceutical company developing a new class of immunotherapies against infectious diseases and cancer based on its arenavirus platform. The chart reflects average profitability expectations for the biotech sector. HOOK's position relative to this benchmark reflects investors' bet on its unique technology and partnerships with major pharmaceutical companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513629030 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing a new class of immunotherapy (arenaviruses) for the treatment of cancer and infectious diseases. It is an innovative scientific platform. This chart of overall market expectations shows how willing investors are to fund risky biotech companies with breakthrough but unproven potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513629044 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit HOOKIPA Pharma Inc.
HOOKIPA Pharma is a biotech company developing a new class of immunotherapies for cancer and infectious diseases based on arenaviral vectors. Its financial structure is comprised of research expenses and partnership revenues. Potential profitability depends on the success of its innovative technology platform.
Profit of companies in the market segment - Pharma immune
HOOKIPA Pharma is a biopharmaceutical company developing a new generation of immunotherapeutic drugs against cancer and infectious diseases based on its arenavirus platform. This chart shows the overall profitability of the immunopharmaceutical industry. It is an indicator of the industry's success in creating and commercializing innovative platforms for stimulating the immune system.
Overall market profit
HOOKIPA Pharma is a biotech company developing a new class of immunotherapy (arenaviruses) for the treatment of cancer and infectious diseases. This is an innovative platform, the success of which depends on the results of clinical trials. The positive economic backdrop, visible in this chart, is important for attracting capital for the development of such cutting-edge technologies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company HOOKIPA Pharma Inc.
HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapeutics for the treatment of cancer and infectious diseases. This chart reflects analysts' speculative expectations regarding the potential of this innovative platform, which is in the early stages of clinical development.
%20profit%20of%20the%20company%20HOOKIPA%20Pharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-HOOKIPA-Pharma-Inc.&v=1772513629121 "Graph of future (projected) profit of the company HOOKIPA Pharma Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
HOOKIPA Pharma is developing a new generation of immunotherapeutic drugs for the treatment of oncology and infectious diseases based on its unique arenavirus platform. The company's future depends on the success of clinical trials. This chart reflects forecasts for the entire biotech sector, providing context for assessing the potential and risks of HOOKIPA's innovative approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513629144 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
HOOKIPA Pharma is a biotech company developing next-generation immunotherapeutic drugs. Its value is determined by progress in clinical trials and partnerships. This earnings curve has little bearing on the company's prospects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513629151 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - HOOKIPA Pharma Inc.
HOOKIPA Pharma is a biotech company developing a new class of immunotherapy based on arenaviruses. Its valuation, shown on this chart, is based not on revenue but on the potential of its unique scientific platform for treating cancer and infectious diseases. The valuation reflects clinical trial news.
P/S market segment - Pharma immune
HOOKIPA Pharma is developing a new class of immunotherapy based on its arenavirus platform for the treatment of cancer and infectious diseases. Future revenue depends on the success of this technology. This pharma chart reflects investor expectations for the potential of HOOKIPA's innovative platform to create a new generation of immunotherapeutics.
P/S of the market as a whole
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapeutics for the treatment of cancer and infectious diseases. This market revenue valuation chart helps understand how investors view this innovative scientific platform and its potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company HOOKIPA Pharma Inc.
HOOKIPA Pharma is a biopharmaceutical company developing a new generation of immunotherapeutic drugs against cancer and infectious diseases based on its arenavirus platform. This chart shows how the market assesses the future commercial potential of its innovative technology, placing its bets on the success of clinical trials and partnerships.
%20P%2FS%20HOOKIPA%20Pharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-HOOKIPA-Pharma-Inc.&v=1772513629237 "The graph of the company's future (projected) P/S HOOKIPA Pharma Inc.")
Future (projected) P/S of the market segment - Pharma immune
HOOKIPA Pharma is developing a new class of immunotherapeutic drugs based on the arenavirus platform for the treatment of cancer and infectious diseases. The company's valuation is based on investors' belief in the potential of its unique technology to stimulate a powerful immune response, potentially leading to the development of breakthrough vaccines and treatments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513629254 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
HOOKIPA Pharma is a biotech company developing a new class of immunotherapy for the treatment of infectious diseases and cancer. It is an innovative scientific platform. Given the overall revenue projections shown in the chart, HOOKIPA represents a venture investment in the future of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513629259 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales HOOKIPA Pharma Inc.
HOOKIPA Pharma is a clinical-stage immuno-oncology company developing a novel class of immunotherapies based on arenaviruses. The company currently has no commercial products, and its revenue, as reflected in the chart, comes from upfront fees and collaboration fees with Gilead Sciences.
Sales of companies in the market segment - Pharma immune
HOOKIPA Pharma (HOOK) is a biotech company developing a new class of arenavirus-based immunotherapeutics for the treatment of cancer and infectious diseases. This chart shows revenue in the immunological pharmaceutical sector. HOOKIPA's innovative platform is capable of inducing a powerful T-cell response, which is key to fighting cancer and viruses.
Overall market sales
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapies for the treatment of cancer and infectious diseases. Its development depends on the success of its scientific platform. This pattern of overall economic activity influences the availability of capital for the biotech sector. During periods of growth, investors are more willing to fund innovative and breakthrough technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company HOOKIPA Pharma Inc.
HOOKIPA Pharma is a biotech company developing a new class of immunotherapeutic drugs (arenaviruses) for the treatment of cancer and infectious diseases. Its future revenue depends on the success of clinical trials and partnerships. This chart reflects analyst forecasts, which assess the potential of its unique technology platform.
%20sales%20of%20the%20company%20HOOKIPA%20Pharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-HOOKIPA-Pharma-Inc.&v=1772513629335 "Schedule of future (projected) sales of the company HOOKIPA Pharma Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
HOOKIPA Pharma is developing a new class of immunotherapy based on its arenavirus platform for the treatment of cancer and infectious diseases. This graph shows the potential future revenue from their developments. This is an analyst's perspective on the commercial prospects of this innovative technology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513629371 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapy for the treatment of cancer and infectious diseases. Its technology is aimed at stimulating a powerful T-cell response. This chart illustrates the overall investment climate, and HOOKIPA's research progress is a bet on an innovative platform that could lead to a breakthrough in immunology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513629390 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality HOOKIPA Pharma Inc.
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapies for the treatment of cancer and infectious diseases. Its financial performance reflects significant investment in this innovative platform. The chart shows current profitability as an investment in the development of potentially breakthrough drugs.
Market segment marginality - Pharma immune
HOOKIPA Pharma is a clinical-stage biopharmaceutical company developing a new class of immunotherapies against infectious diseases and cancer based on its arenavirus platform. This chart reflects its operating expenses. Future profitability depends on the success of its innovative technology.
Market marginality as a whole
HOOKIPA Pharma is a biopharmaceutical company developing a new class of immunotherapy based on arenaviruses. It is at the forefront of science and relies on investment. This total return chart reflects the market's willingness to fund breakthrough but high-risk platforms. Economic optimism is driving capital inflows into such companies.
Employees in the company, segment and market as a whole
Number of employees in the company HOOKIPA Pharma Inc.
HOOKIPA Pharma is an Austrian biotech company developing a new class of arenavirus-based immunotherapy for the treatment of cancer and infectious diseases. This graphic shows the team of scientists working on this innovative platform to train the body's immune system to fight disease.
Share of the company's employees HOOKIPA Pharma Inc. within the market segment - Pharma immune
HOOKIPA Pharma is using its unique technology platform to develop a new class of immunotherapies against infectious diseases and cancer. In biotechnology, the scientific staff is a key asset. This chart shows the amount of intellectual capital the company is investing in developing its cutting-edge scientific platform and advancing its candidates to the clinic.
Number of employees in the market segment - Pharma immune
HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapies for the treatment of cancer and infectious diseases. This graph, showing activity in the immunopharmaceutical sector, illustrates the ongoing search for new platforms. For HOOKIPA, with their unique technology, growth in this field means both recognition of their approach and intense competition.
Number of employees in the market as a whole
HOOKIPA Pharma is using its innovative platform to develop a new class of immunotherapeutic drugs against infectious diseases and cancer. Funding for such breakthrough technologies is possible in a healthy economic environment. The growth in overall employment shown in this chart is a sign of such an environment, which attracts venture capital to the biotech sector.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma (HOOK) is a biotech company developing immunotherapeutic drugs (including cancer treatments). This chart shows the valuation of their unique R&D platform. Market capitalization is not tied to headcount but rather reflects the success of their technology. This is pure intellectual capital, which translates into a high valuation per employee.
%20of%20the%20company%20HOOKIPA%20Pharma%20Inc.%20(HOOK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-HOOKIPA-Pharma-Inc.-HOOK&v=1772513629682 "Chart of market capitalization per employee (in thousands of dollars) of the company HOOKIPA Pharma Inc. (HOOK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
HOOKIPA Pharma is developing a new class of immunotherapy based on its unique platform. In biotech, market capitalization reflects the potential of the scientific platform. This chart shows the market premium a company places on its innovative technology, based on its focused scientific team.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513629708 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
HOOKIPA Pharma is a biotech company developing a new class of arenavirus-based immunotherapies for the treatment of cancer and infectious diseases. This is cutting-edge science. This chart for HOOKIPA illustrates how the cost per employee in the immunotherapy space can be astronomical, reflecting the complexity and potential of their technology platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513629773 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma is a biotech R&D company working in the field of immunotherapy. Like its peers in the sector, it is profitless. This chart shows expenses, not revenue: the loss (investment) per employee working on clinical trials and drug development.
%20Chart%20HOOKIPA%20Pharma%20Inc.%20(HOOK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-HOOKIPA-Pharma-Inc.-HOOK&v=1772513629865 "Company Profit Per Employee (in thousands of dollars) Chart HOOKIPA Pharma Inc. (HOOK)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
HOOKIPA Pharma is developing a new class of arenavirus-based immunotherapy for the treatment of cancer and infectious diseases. In advanced biotechnology, the productivity of the research team is critical. This graph shows the potential value generated by each employee, an indicator of the effectiveness of the company's innovative platform.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513629884 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
HOOKIPA Pharma is a biotech company developing a new class of immunotherapy (arenaviruses) for the treatment of cancer and infectious diseases. It's an R&D platform. This chart, showing the market average profit per employee, provides important context. It illustrates how high the stakes are in biotech, where a single successful R&D platform can generate colossal profits per scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513629910 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma is a biotech company developing next-generation immunotherapeutic drugs for cancer and infectious diseases. While in clinical trials, its revenue is generated through partnerships. The chart shows these partnership revenues, which help fund its innovative scientific platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-HOOKIPA-Pharma-Inc.-HOOK&v=1772513629943 "Sales chart per company employee HOOKIPA Pharma Inc. (HOOK)")
Sales per employee in the market segment - Pharma immune
HOOKIPA Pharma (HOOK) is a biotech company developing next-generation immunotherapies (based on arenaviruses) for the treatment of cancer and infectious diseases. This chart shows the average revenue per employee in the sector. It is important for assessing R&D efficiency and capital utilization compared to other immuno-oncology companies.
Sales per employee for the market as a whole
HOOKIPA Pharma (HOOK) is a clinical-stage biotechnology company developing a new class of immunotherapy (based on arenaviruses) for the treatment of cancer and infectious diseases. The company has no commercial revenue. This near-zero figure reflects investment in the team of scientists working on this unique technological platform.
Short shares by company, segment and market as a whole
Shares shorted by company HOOKIPA Pharma Inc. (HOOK)
HOOKIPA Pharma (HOOK) is a clinical-stage biotech using its proprietary arenavirus platform to develop cancer immunotherapies. This chart shows short interest. The high bearish bets reflect the risks associated with a new, unproven technology platform and the intense competition in the immuno-oncology field. (340)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-HOOKIPA-Pharma-Inc.-HOOK&v=1772513629988 "Short Shares Chart for the Company HOOKIPA Pharma Inc. (HOOK)")
Shares shorted by market segment - Pharma immune
HOOKIPA Pharma (HOOK) is a biopharmaceutical company developing next-generation immunotherapies (arenaviruses) for the treatment of cancer and infectious diseases. The chart below represents a general short position in the biotech sector. It demonstrates the general investor skepticism regarding the success of new, complex platforms.
Shares shorted by the overall market
HOOKIPA Pharma is a biotech company developing a new immunotherapy platform. This is complex and expensive science. This chart illustrates the general fear. When investors are pessimistic, they are unwilling to fund R&D, which could take 10 years. They see HOOK as a money-burner and a binary risk (failure/success), preferring to sell the shares and avoid the risk.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator HOOKIPA Pharma Inc. (HOOK)
HOOKIPA is a biotech company using arenaviruses to develop a new class of immunotherapy (for cancer and infections). This is R&D at the cutting edge of science. This graph is a "cardiogram" of hope. It "overheats" on positive trial data or partnerships (like with Gilead) and "cools" in anticipation of further news.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-HOOKIPA-Pharma-Inc.-HOOK&v=1772513630104 "RSI 14 indicator chart for the company's stock HOOKIPA Pharma Inc. (HOOK)")
RSI 14 Market Segment - Pharma immune
HOOKIPA Pharma is an Austrian biotech company developing a new generation of immunotherapies (arenaviruses) for the treatment of cancer and infectious diseases. This chart measures the overall momentum of the immunology biotech sector. It clearly shows when this entire niche is overheated by expectations or oversold by setbacks.
RSI 14 for the overall market
HOOKIPA Pharma (HOOK) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HOOK (HOOKIPA Pharma Inc.)
HOOKIPA Pharma is a biotech company developing a new class of immunotherapy (arenavirus platform) for the treatment of cancer and infectious diseases. This chart shows the speculative average price target from analysts, which is almost entirely based on their assessment of the scientific potential of the R&D portfolio and clinical trial data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HOOK-HOOKIPA-Pharma-Inc.&v=1772513630158 "A chart showing analyst consensus forecasts for the expected stock price. HOOK (HOOKIPA Pharma Inc.)")
The difference between the consensus estimate and the actual stock price HOOK (HOOKIPA Pharma Inc.)
HOOKIPA is a biotech company developing a new class of immunotherapy (arenaviruses) for the treatment of cancer and infections. This chart shows how far the current share price differs from the "fair" value predicted by analysts. The gap reflects their "venture capital" valuation of this unique R&D platform and its chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HOOK-HOOKIPA-Pharma-Inc.&v=1772513630173 "A chart showing the difference between the consensus forecast and the actual stock price. HOOK (HOOKIPA Pharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
HOOKIPA Pharma is a clinical-stage biotech company using its "arenavirus" platform to develop new cancer immunotherapies. This is high-risk R&D. This chart shows the collective analyst consensus on the *entire* immunopharmaceutical sector. It reflects whether experts are willing to take risks on new platforms.
Analysts' consensus forecast for the overall market share price
HOOKIPA Pharma is a biotech company developing a platform for immunotherapy for cancer and infectious diseases. This is a high-risk sector. This chart reflects the overall market "risk appetite." For HOOK, a clinical-stage company, overall market optimism (a rising chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index HOOKIPA Pharma Inc.
HOOKIPA is an R&D company in immuno-oncology. Their signature feature is an R&D platform (arenavirus), which uses a tamed virus (like a Trojan horse) to train the immune system (T-cells) to attack cancer (HPV16+) and infections (Hepatitis B). This chart is a pure R&D barometer of faith/fear. It doesn't reflect sales, but rather the market's speculative valuation of their (very risky) pipeline and clinical data.
AKIMA Market Segment Index - Pharma immune
HOOKIPA Pharma uses an innovative arenavirus platform to train the immune system to attack cancer and infections. This is a complex but promising field of immunology. This chart compares their composite index to the sector average, allowing us to assess how their unique technology (HOOK) is ahead of the competition in this race.
The AKIM Index for the overall market
HOOKIPA Pharma is a biotech company developing cancer immunotherapies and vaccines based on the arenavirus platform. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story involving the Gilead partnership compares to overall economic trends in biotech.
